Amneal Pharmaceuticals, Inc (AMRX) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Amneal (AMRX) Q2 2026: Biosimilar Pipeline Expands to Six Launches, Unlocking $14B Market Access
  July 30, 2026
• Amneal (AMRX) Q1 2026: Biosimilars to Surpass $1B by 2030 as Kashiv Deal Reshapes Growth Trajectory
  May 01, 2026
• Amneal Pharmaceuticals (AMRX) Q4 2025: Specialty Segment Jumps 38% as Complex Launches Reshape Growth Mix
  February 27, 2026
• Amneal Pharmaceuticals (AMRX) Q3 2025: Biosimilar Pipeline Expands to Six as Guidance Rises Again
  October 30, 2025
• Amneal (AMRX) Q2 2025: Gross Margin Expands 470bps as Specialty Growth and U.S. Manufacturing Drive Guidance Raise
  August 05, 2025
• Amneal (AMRX) Q2 2025: Gross Margin Up 470bps as Specialty and Biosimilars Drive Next-Phase Growth
  August 05, 2025
• Amneal (AMRX) Q1 2025: Biosimilars Top $160M as U.S. Manufacturing Drives Margin Expansion
  July 06, 2025

Browse all companies